**Question:** Which of the following parameters is not monitored in a patient on methotrexate therapy?

A. Complete Blood Count (CBC)
B. Serum Creatinine
C. Electrolytes
D. Urine Analysis

**Core Concept:** Monitoring parameters in patients on methotrexate therapy is essential to assess the drug's side effects and toxicity. Methotrexate is an antifolate drug used in the treatment of various cancers and autoimmune disorders.

**Why the Correct Answer is Right:** Among the given options, urine analysis is not a standard parameter monitored in patients on methotrexate therapy. This is because methotrexate primarily affects the liver and kidney function, rather than urine analysis, which is mainly useful for assessing renal function. Monitoring CBC, serum creatinine, and electrolytes allows for evaluation of potential toxicity, such as bone marrow suppression, renal impairment, and electrolyte imbalances, respectively.

**Why Each Wrong Option is Incorrect:**

A. Complete Blood Count (CBC): Monitoring CBC is crucial in assessing methotrexate-induced bone marrow suppression. Leukopenia, thrombocytopenia, and anemia are common side effects that should be detected early to adjust the dosage or switch to an alternative therapy.

B. Serum Creatinine: Monitoring serum creatinine is essential for detecting methotrexate-induced renal toxicity. Elevated creatinine levels indicate impaired kidney function, allowing for timely adjustment of the drug dosage or intervention.

C. Electrolytes: Monitoring electrolytes, particularly serum potassium and magnesium, helps detect methotrexate-induced electrolyte imbalances. Imbalances can lead to serious complications, thus early detection and intervention are crucial.

D. Urine Analysis: As mentioned earlier, urine analysis is primarily used to assess renal function, which is not a primary concern when monitoring methotrexate therapy. CBC, serum creatinine, and electrolytes are more relevant for assessing methotrexate-induced side effects.

**Clinical Pearl:** In methotrexate therapy, it is crucial to consider the patient's clinical presentation, response to therapy, and liver function tests (LFTs) along with the monitored parameters mentioned above. Early detection of toxicity enables timely adjustment of the drug regimen, ensuring optimal treatment outcomes and minimizing the risk of severe complications.